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Abstract. Yaws is a neglected infectious disease that affects mostly children and adolescents living in poor, rural
communities in humid, tropical areas of Africa, southeast Asia, and the Pacific Islands. The etiological agent of yaws,
Treponema pallidum subspecies pertenue (T. pertenue), was discovered by Aldo Castellani in 1905 shortly after Schaudinn
and Hoffmann discovered the etiological agent of syphilis, T. pallidum subspecies pallidum. The discovery of T. pertenue
enabled the development of animal models and the identification of an effective antibiotic treatment (i.e., penicillin) for
yaws. A World Health Organization (WHO) mass treatment campaign from 1952 to 1964 reduced the global burden of
yaws by 95%, but failed to eradicate this disease. Today, 110 years after Castellani’s discovery of T. pertenue, yaws is again
targeted for eradication. Recent advances in the treatment and diagnosis of yaws improve the likelihood of success this
time. However, several challenges must be overcome to make the goal of yaws eradication attainable.
Yaws is an infectious disease that affects mostly children and
adolescents, aged 2–15 years, who live in poor, rural communi-
ties in humid, tropical areas of Africa, southeast Asia, and the
Pacific Islands.1 Yaws is currently thought to be endemic in at
least 12 countries, but adequate surveillance data are lacking.2
This disease is transmitted by contact of broken or abraded
skin with the exudate of yaws lesions. Clinical manifestations
of yaws are divided into stages. Early stage skin lesions are
infectious and can persist for weeks or months. Involvement of
the bones of the upper and lower limbs and the fingers and toes
can cause pain and digital swelling. After the early stage lesions
subside due to the host immune response, the patient enters a
latent stage that can be lifelong. In about 10% of untreated
patients, the infection progresses to the tertiary stage that is
characterized by destruction of tissue, bone, and cartilage
resulting in disfigurement and disability.1
The etiological agent of yaws, T. pallidum subspecies
pertenue (i.e., T. pertenue), was discovered in 1905 by Aldo
Castellani, a physician and expert in neglected tropical dis-
eases. Castellani had observed spiral-shaped bacteria in lesion
material from yaws patients in Sri Lanka (formerly Ceylon),
but did not ascribe significance to this observation. However,
after learning of the 1905 discovery of the syphilis agent,
T. pallidum subspecies pallidum (i.e., T. pallidum), by Schaudinn
and Hoffmann3 and cognizant of the similarities of syphilis and
yaws, Castellani examined new scrapings from yaws lesions.
Using special staining techniques, he again observed delicate,
faintly stained spirochetes that were morphologically indistin-
guishable from T. pallidum. Castellani’s preliminary findings
were presented to the Ceylon Branch of the British Medical
Association in June 1905.4 After studying lesion material from
additional yaws cases, he proposed “Spirochaeta pertenuis” (i.e.,
T. pertenue) as the etiological agent of yaws.5,6 Castellani’s
findings were soon confirmed by the December 1905 report of
Wellman, who had observed spirochetes in the lesions of an
African yaws patient.7
The discovery of T. pertenue enabled the development of
animal models for experimental studies of yaws. Castellani
investigated the infectious nature of the noncultivable
T. pertenue in monkeys.8 He showed that 1) monkeys could
be experimentally infected with an inoculum prepared from
the lesions of yaws patients, 2) the inoculum could be ren-
dered noninfectious by removal of T. pertenue by filtration,
and 3) yaws could be serially transferred in monkeys, and
T. pertenue was invariably present in “pure culture” in the
monkeys’ non-ulcerated lesions. Using a modification of
Wassermann’s complement fixation test for serodiagnosis of
syphilis, Castellani detected antibody reactivity in the sera
of yaws-infected monkeys, but not naı̈ve monkeys, to antigen
in an extract of yaws lesions.8 In addition, Castellani demon-
strated that yaws-infected monkeys were not immune to syph-
ilis and, conversely, that syphilis-infected monkeys were not
immune to yaws (i.e., there is no cross-protection conferred
by infection).8 This observation along with the previously
published work of Neisser and co-workers,9 dispelled the
belief that syphilis and yaws were the same disease, but with
different clinical manifestations because of host genetics and
climate. In 1910, Nichols reported that rabbits could be
infected intratesticularly with T. pertenue and proposed that
these animals could provide a more practicable model of yaws
for the investigation of immunity and treatments.10
Because of the biological similarities of T. pallidum and
T. pertenue, there was optimism that syphilis treatments
would be effective for yaws. In 1907, Castellani reported the
results of various syphilis treatments on small numbers of
yaws patients.11 He noted a dramatic improvement of yaws
lesions following administration of mercury by the oral or
intramuscular route. However, as observed with syphilis, mer-
curials alone were not curative because yaws lesions usually
reappeared after treatment cessation. In 1910, salvarsan
(compound 606), an arsenical developed by Ehrlich in
Germany, showed promising results for syphilis treatment.12
Castellani noted that salvarsan was more effective than mer-
cury for yaws treatment.13,14 Strong (1911), Alston (1912),
Cockin (1913), and McDonald (1915) reported that one injec-
tion of salvarsan, given intravenously or intramuscularly,
could cure early and late yaws.15–18 The few relapses, or pos-
sible reinfections, which occurred were successfully retreated
with salvarsan. Interestingly, salvarsan appeared to be more
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effective for yaws than it was for syphilis. Nichols postulated
that the need for prolonged treatment of syphilis with salvarsan
was due to the more invasive nature of T. pallidum, which
enabled it to survive in body sites where the concentration of
salvarsan was subtherapeutic.19 In 1914, Ehrlich developed
neosalvarsan (compound 914), which was easier to administer
and had less side effects than salvarsan.12 Harper20 and
Greggio14 reported that neosalvarsan was effective for yaws
treatment. Later, mapharsen, a partially oxidized product of
salvarsan, was found to cure syphilis.12 This arsenical, which
was patented in 1937, was less toxic than neosalvarsan and could
be given in smaller doses. Longley and co-workers21 showed
that both mapharsen and neosalvarsan were effective for curing
rabbits infected with yaws. However, the use of mapharsen for
yaws treatment was limited because arsenicals essentially
became obsolete when penicillin became available in the
1940s. Following the 1943 report of Mahoney and co-workers22
on the curative action of penicillin for syphilis, there were
multiple reports of small numbers of yaws cases that were
cured with penicillin.23 Dwindelle and co-workers23 treated
500 Haitian patients in early yaws with penicillin and demon-
strated the therapeutic efficacy of this drug, which became
the mainstay for the treatment and control of yaws.
Nearly 50 years after Castellani’s discovery of T. pertenue, a
major effort was made to eradicate yaws. From 1952 to 1964,
the WHO, in concert with the United Nations Children’s
Fund (UNICEF), sponsored a mass treatment campaign in
46 countries.1,2,24 About 300 million people were screened
and 50 million or more cases and their contacts were treated
with an intramuscular injection of long-acting penicillin. By
the end of this campaign, the global burden of yaws was
reduced by 95% to 2.5 million cases. Unfortunately, the lack
of sustained surveillance and the waning of commitment and
resources resulted in the reemergence of yaws in Africa, Asia,
and the Pacific in the late 1970s. Although control activities
were renewed in several countries and efforts were made to
galvanize support from the international community, yaws
eradication failed.
Today, 110 years after the discovery of T. pertenue, yaws is
again targeted for eradication. TheWHO’s “Morges strategy”
for yaws eradication by 2020 is based on mass treatment of
individuals in endemic communities followed by clinical and
serological surveys at 6-month intervals to detect and treat the
remaining cases and their contacts.24,25 Two recent advances
for treatment and diagnosis of yaws should greatly aid eradi-
cation efforts. First, Mitja and others showed in two separate
studies conducted in Papua New Guinea that a single, oral
dose of azithromycin (30 mg/kg body weight; maximum dose
of 2 g) is as effective as intramuscular benzathine penicillin
(1.2 million units (MU) for adults, 0.6 MU for children) for
yaws treatment and is more feasible to administer in the
field.26,27 Azithromycin, which has recently replaced penicillin
as the WHO-preferred drug for yaws, will be used for mass
treatment in communities where yaws is endemic. Second,
Ayove and others28 showed that a point-of-care serological
test for syphilis diagnosis, the Dual Path Platform (DPP)
Syphilis Screen and Confirm, is sufficiently sensitive and spe-
cific for rapid diagnosis of yaws under field conditions using
finger-stick blood. This important development obviates the
need for venipuncture to obtain serum samples and for trans-
port of serum samples to a distant laboratory for testing. The
DPP test will be used to detect yaws cases that are difficult
to diagnose based on clinical symptoms because unrelated
bacteria, such as Haemophilus ducreyi, can cause phenotypi-
cally similar skin lesions.1 The DPP test may also be used for
monitoring the effectiveness of azithromycin treatment.
Undoubtedly, many challenges must be overcome for yaws
eradication to succeed. Aside from major financial and com-
mitment issues, several uncertainties related to the biology
and epidemiology of yaws could impede this endeavor.1,2,29
Because there is no vaccine to prevent infection, antibiotic
treatment must be effective to interrupt transmission of yaws.
The use of oral azithromycin as the first-line drug, while war-
ranted based on logistics, could result in the emergence of
azithromycin-resistant T. pertenue, as has been observed with
T. pallidum.30,31 This possibility requires careful monitoring.
Furthermore, although the prevalence of yaws is undoubtedly
less than it was at the time of the first WHO eradication
campaign, the current burden and distribution of yaws are
unknown.2,24 The inability to find and treat yaws cases, partic-
ularly in remote areas of previously endemic countries that
have not reported cases to the WHO since 1990, could allow
yaws to resurface. Despite these concerns, recent advances in
the treatment and diagnosis of yaws and a more favorable
climate for control of neglected tropical diseases have
renewed hope that yaws eradication can be achieved. What
more fitting tribute could there be to Aldo Castellani, the
discoverer of T. pertenue, than to finally vanquish this “end
of the road” disease?
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